Platelia™ Candida Ag Plus
Platelia™ Candida Ab Plus
When Early Diagnosis Saves Lives
Platelia™ Candida Ag Plus - Platelia™ Candida Ab Plus

Monitoring of patients at-risk for invasive candidiasis

<table>
<thead>
<tr>
<th>Early diagnosis</th>
<th>Fast initiation of appropriate antifungal treatment</th>
</tr>
</thead>
</table>

Candida infections rank as the first cause of nosocomial fungal infections; candidemias are the fourth cause of nosocomial blood stream infections.

Invasive candidiasis represent the most serious forms of Candida infections with a mortality rate ranging from 30 to 70% in immunosuppressed patients and 30 to 40% in patients hospitalized in intensive care units. Their diagnosis is still difficult due to the lack of specificity of the clinical symptoms and the poor sensitivity of the blood culture. The diagnosis of invasive candidiasis, leading to initiation of appropriate treatment, is usually based on a combination of data: it must associate serological techniques with direct mycological methods. The detection of circulating antigens in serum or plasma appears to improve the diagnosis in patients at risk for invasive candidiasis.

The major risk factors include neutropenia after chemotherapy or immunosuppressive treatment (in cancer, oncohematological and transplant patients), wide spectrum antimicrobial therapy, venous catheters, parental nutrition, renal dialysis, implanting of prostheses (in patients hospitalized in medical or surgical intensive care units).

Amongst Candida antigens, mannan is a highly immunogenic polysaccharide bound to the yeast cell-wall. It appears to be one of the main biomarkers for the diagnosis of invasive candidiasis.

The regular monitoring of at-risk patients, combining the detection of circulating mannan antigen (Platelia™ Candida Ag Plus) and anti-mannan antibodies (Platelia™ Candida Ab Plus), is an aid to improve the earliness of the diagnosis of invasive candidiasis. It can help physicians in initiating prompt and appropriate antifungal therapy, resulting in life saving and decreased morbidity.

Simple
- Standard EIA procedure

Flexible
- Serum or plasma samples

Convenient
- 96-well microplate with breakable strips
- Ready-to-use, colored reagents (diluents, calibrators, conjugate, chromogen)

Secured
- Visual control of sample dilution
- Visual control of reagent deposit

Objective
- Results reported as pg/ml(Ag)
- Results reported as AU/ml(Ab)

Quick
- 2h00 (Ag), 2h30 (Ab) turnaround time

Efficient
- Enhanced sensitivity
- Faster initiation of appropriate treatment

Automated
- Fully automated on Bio-Rad Systems: EVOLIS™ Premium, EVOLIS™ Twin Plus, PR 3100

Economical
- Improved laboratory workflow
- Hospitalization cost savings

Ordering Information

<table>
<thead>
<tr>
<th>Catalog No.</th>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>62784</td>
<td>Platelia™ Candida Ag Plus</td>
<td>96 tests</td>
</tr>
<tr>
<td>62785</td>
<td>Platelia™ Candida Ab Plus</td>
<td>96 tests</td>
</tr>
</tbody>
</table>

For further information, please contact the Bio-Rad office nearest you or visit our website at www.bio-rad.com/diagnostics